List view / Grid view
In this Genomics / Sequencing supplement: NGS powers up drug discovery and healthcare; Impact of novel sequencing technology on transcriptome analysis; Making sense of nonesense (and missense): Bringing the results of recent genetic studies into the drug discovery laboratory...
28 August 2011 | By Bristol-Myers Squibb Company, Pfizer
Significantly less major bleeding in patients with Atrial Fibrillation in Phase 3 ARISTOTLE trial...
23 August 2011 | By Pfizer
New data presentations from largest Phase 3 Clinical Trial Program for Stroke Prevention in Atrial Fibrillation...
17 August 2011 | By Pfizer
EMA accepted Pfizer’s regulatory submissions for review of two investigational compounds...
15 August 2011 | By Pfizer
Pfizer Inc. has prevailed in its patent infringement action against Teva Pharmaceuticals USA, Inc. in the United States District Court for the Eastern District of VA...
8 August 2011 | By Pfizer
Five year partnership With UC San Diego Health Sciences to accelerate drug discovery and development...
3 August 2011 | By Pfizer
NCCN has received a $2 million educational grant from Pfizer to help support the first CME program...
1 August 2011 | By Pfizer
Pfizer Inc. has completed the sale of its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. L.P...
29 July 2011 | By Pfizer
The U.S. FDA issued a 90-day extension to the action date for the Company’s sBLA for use of Prevnar 13®...
20 July 2011 | By Pfizer
Pfizer Inc. and Icagen, Inc. announced that they have entered into a definitive merger agreement....
5 July 2011 | By Pfizer
Pfizer Japan announced the top-line results for Lyrica (pregabalin) Study A0081208...
4 July 2011 | By Pfizer
An effective and appropriate treatment option for adult smokers wanting to quit...
29 June 2011 | By Pfizer
Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio...
28 June 2011 | By Pfizer
The U.S. FDA has accepted Pfizer’s filing for standard review of axitinib for patients with advanced RCC...
24 June 2011 | By Pfizer
Pfizer & Pain Therapeutics, Inc. received a Complete Response Letter from the U.S. FDA...
